Covid-19 is Best Managed by non-infectious disease experts

While early SARS-CoV-2 exposure can be well managed by infectious disease experts, Big Pharma, as well as the 3-letter agencies (FDA, CDC, NIH) have almost ensured these experts don’t have the tools and information for successfully managing early SARS-CoV-2 exposure before patients develop full blown Covid-19 symptoms or require hospitalization. Once patients develop full blown Covid-19, they are no longer in the area of expertise or training of the typical infectious disease expert. The CDC or NIH may not tell you this, but that’s a scientific reality; full-blown Covid-19 is a cytokine disorder not an infection that responds to antivirals or antibiotics. Most hospitalized patients with severe Covid-19 symptoms are suffering from cytokine overload for which neither antivirals or antibiotics have any primary role in treating. The experts that routinely treat cytokine and small molecule disorders are oncologists, rheumatologists, immunologists and less frequently pulmonologists. They are the most likely experts to offer hospitalized Covid-19 patients the best possible outcomes. You’ll never find any serious recommendations from the NIH or CDC to involve oncologists, rheumatologists, or immunologists, in the care of hospitalized Covid-19 patients. Placing the care of such sick Covid-19 patients solely in the hands of a typical infectious disease expert is negligence. It has cost many their lives.